We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Preventing Malaria with Antibodies That Block Formation of Red Cell Rosettes

By LabMedica International staff writers
Posted on 30 Apr 2012
Molecular biologists working on malaria have prepared antibodies that block the activity of a protein common to most Plasmodium falciparum strains that generates the red blood cell rosettes that are responsible for symptoms of the severe illness, including coma and brain damage.

The PfEMP1 family of variant surface antigens, which are encoded by var genes, are adhesion molecules that play a pivotal role in malaria pathogenesis and clinical disease. More...
PfEMP1 is a major target of protective immunity; however, development of drugs or vaccines based on PfEMP1 is problematic due to extensive sequence diversity within the PfEMP1 family. In the current study, investigators at the University of Edinburgh (United Kingdom) focused on a single manifestation of PfEMP1activity, the ability to generate rosettes (clumps) of red blood cells.

They reported in the April 19, 2012, online edition of the journal PLoS Pathogens that they were able to generate antibodies against PfeMP1 that blocked rosette formation. The antibodies showed broad cross-reactivity against heterologous parasite strains with the same rosetting phenotype, including clinical isolates from four sub-Saharan African countries.

Senior author Dr. Alexandra Rowe, professor of immunology at the University of Edinburgh, said, “We knew that clusters, or rosettes, of blood cells were found in many cases of severe or life-threatening malaria, so we looked at rosette-forming parasites and found a common factor that we could target with antibodies. We hope this discovery will inform new treatments or vaccines to block the formation of rosettes and so prevent many life-threatening cases of malaria.”

The existence of shared surface epitopes amongst functionally similar disease-associated P. falciparum parasite isolates suggests that development of therapeutic interventions to prevent severe malaria is a realistic goal.

Related Links:

University of Edinburgh



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Urinalysis Solution
UN-9000
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.